secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001493152-24-031340
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences reports Q2 2024 net loss of $1.7M; prioritizes EB-003 as lead candidate
--------------------------------------------------------------------------------

- Net loss of $1.7M ($0.23/share) vs $6.4M loss in Q2 2023; cash on hand $3.5M.
- Prioritized EB-003, a non-hallucinogenic neuroplastogenic molecule, as lead development candidate.
- Preclinical data confirms oral bioavailability and brain exposure of EB-003; IND filing expected Q3 2025.
- Signed licensing agreement with Aries Science & Technology for radiation dermatitis product; non-binding term sheets for joint disease and cancer treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315224031340/0001493152-24-031340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315224031340/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer